Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Corporate Webcast: Silence Therapeutics AG (SNL) - Pre-Clinical And Clinical Development Of Atu027, A Liposomal SiRNA, For Therapy In Oncology.

Silence Therapeutics AG (SNL) - Pre-Clinical and Clinical Development of Atu027, a Liposomal siRNA, for Therapy in Oncology.

Atu027, a novel RNAi therapeutic composed of liposomally formulated siRNA, is currently being tested in a Phase I clinical trial in oncology. This investigational drug targets the expression of PKN3 in the vascular endothelium and shows inhibition of tumor growth and strong anti-metastatic activity in various pre-clinical models. Latest developments on Atu027 will be discussed.

Broadcast live, record and publish your investor, corporate and analyst videos on 3B NEXUS for our targeted distribution.